Occidental Petroleum Corporation (NYSE: OXY) — A No-Moat Price-Taker Already Paid Up for Its Own Fix

Occidental Petroleum Corporation (NYSE: OXY) Sector: Energy — Oil & Gas Exploration & Production (Permian-weighted), plus Midstream & Marketing and Low Carbon Ventures (1PointFive DAC/CCUS) GICS sub-industry: Integrated Oil & Gas (functionally a large-cap US independent E&P post-OxyChem divestiture) Date: 2026-06-04 · Price at writing: ~$58.67 · Diluted shares: ~1,023M · Common market cap: ~$57.8B · EV (incl. preferred): ~$78B CEO: Richard A. Jackson (effective 2026-06-01; succeeded Vicki Hollub, who remains on the Board) · Largest holder: Berkshire Hathaway (~26.6% of common + $8.5B 8% preferred + 83.9M warrants)

Every material claim traces to a primary source. Figures are reconciled to the FY2025 Form 10-K (filed 2026-02-18) and Q1 2026 Form 10-Q (filed 2026-05-05) unless noted. Third-party market data is flagged as unofficial.

⚡ Claude’s Take

This block is the author’s own subjective opinion. It is the single place in this document where a position is taken, and it is not investment advice — it is general information only. Everything below it (Sections 1–15) is analysis that carries no recommendation and no price target — valuation there is discussed only as embedded expectations and scenarios.

Verdict: HOLD / AVOID-at-this-price — a competently-run, above-average-asset commodity E&P that is fully-to-richly priced today. Accumulate only on a washout into the low-to-mid $40s (Buffett’s revealed zone); not a short. Conviction: medium.

Directional zone: I’d want to own OXY in the ~$40–48 band (≈1.5x tangible book, where Berkshire was an aggressive buyer and where a mid-cycle-$65 WTI FCF yield clears ~9–11%). I regard ~$55–62 as mid-cycle-fair-to-full, and above ~$62–65 as paying up for a no-moat price-taker into a maturing basin with a return-capping preferred. The stock at ~$59 sits right at the $59.59 Berkshire warrant strike and at the top of Buffett’s accumulation range — the most patient, structurally-advantaged value buyer in the market bought hand-over-fist in the $40s and stopped adding above the mid-$50s (no purchase since Feb 2025). That is the cleanest single tell I have.

Why. This is a falling-knife-turned-fixer-upper that has already been mostly fixed — and the market has paid for the fix. The bull story (deep Permian inventory, Berkshire halo, rapid de-levering, DAC optionality) is real but fully reflected: on a correctly preferred-adjusted EV/EBITDAX of ~7.4x, OXY trades at a full-to-rich multiple versus lower-leverage, lower-breakeven, share-shrinking peers (EOG ~6.3x, COP ~6.9x, DVN ~5.3x). The “cheap” 14.7x forward P/E is an optical artifact of DD&A and the $679M preferred dividend crushing the EPS denominator. Strip the Strait-of-Hormuz war premium currently inflating spot cash flow (Brent ~$95–97 vs. an EIA mid-cycle pull toward ~$79 by 2027) and the equity is a levered, unhedged call on WTI whose through-cycle ROE is ~6% at mid-$60s oil — below its cost of capital. The framing is momentum-against-value: the tape is bullish (oil spiking), the fundamentals say wait. I will not chase a price-taker on a geopolitical spike.

What flips me. Bullish trigger: a genuine, oil-uncorrelated re-rating — STRATOS DAC printing sub-$200/t capture costs with firm above-cost offtake (turning the DAC option from negative-carry to a real second leg), or a price reset into the low-$40s that restores a margin of safety. Bearish trigger: a sustained sub-$55 WTI reversion once Hormuz reopens — at $55 the $679M preferred + $0.96 dividend are uncovered by FCF, de-levering stalls, and the senior preferred squeezes the common. Tag: “Buffett’s buy price is in the $40s — so is mine.”

1. Executive Summary

Occidental is a large-cap, Permian-weighted US oil & gas producer that, as of January 2026, has reverted to a near-pure upstream commodity business. The defining recent event is the sale of OxyChem — its chemicals segment — to Berkshire Hathaway for $9.7B all-cash, closed January 2, 2026 (≈$3.2B after-tax gain; now reported as discontinued operations). That transaction removed the one franchise in the portfolio with a genuine, structural cost-advantage moat (US feedstock-advantaged chlor-alkali/PVC) and routed every dollar of proceeds to debt reduction — confirming that leverage, not opportunity, has been the binding constraint on this company.

The investment character is unambiguous: OXY is an above-average asset base with no durable, firm-level competitive moat. Oil is a globally fungible commodity; OXY is a price-taker that was fully unhedged at year-end 2025. Its only candidate moat in Greenwald’s taxonomy is a cost advantage, and that is middling — cash lifting cost is low and falling ($8.94/Boe in 2025, down ~15% over three years), but independent sell-side coverage flags OXY’s remaining-inventory breakeven as among the highest in North American E&P coverage. The one genuinely hard-to-replicate edge is its CO₂-enhanced-oil-recovery franchise (34 active floods, 50+ years, 1.4M Permian EOR acres, 2.8 Bcf/d of CO₂ infrastructure) — a real low-decline annuity, but small relative to the whole and still WTI-dependent.

Financially, the senior balance sheet has been materially de-risked: face debt fell from $24.4B (YE2024) to $20.4B (YE2025) to ~$13.8B (March 2026), targeting ~$10B. But the $8.5B Berkshire 8% preferred sits outside that figure, costs $679M/year, cannot be voluntarily redeemed before August 2029, and — through a mandatory 10%-premium redemption trigger on common distributions above $4.00/share — caps buybacks and dividends. OXY ran zero buybacks in 2025 while peers shrank their share counts; OXY’s count is rising (warrant exercises). Returns are entirely WTI-set and currently unexceptional (~6% ROE on common at mid-$60s oil).

The capital-allocation record is mixed, tilting negative: the 2019 Anadarko acquisition (~$55B, a top-of-cycle bidding-war win over Chevron, debt- and preferred-funded) nearly destroyed the equity in 2020 (-$14.8B loss, ~86% dividend cut) and created the preferred handcuff that still binds. CrownRock (2024, ~$12.4B) repeated the debt-funded pattern more sensibly. The recent cleanup is competent, and — a genuine positive — management’s incentive comp is return-based (CROCE, FCF, relative TSR), not production-growth-based, with >94% say-on-pay support.

On valuation, the market is paying ~$78B EV (preferred-inclusive) against a proved-reserve PV-10 of $36.6B — a ~$41–44B premium for unproved Permian inventory, an above-SEC-deck mid-cycle oil price, midstream, and DAC optionality. Reverse-engineered, the price embeds a constructive mid-cycle WTI of roughly $68–75 and flawless de-levering/execution. It does not discount a structural reversion to the $50s. This analysis takes no position and sets no price target; the discussion below frames the embedded expectations and the scenarios. The single most important question for any OXY thesis is not the company — it is the oil price, which OXY does not control.

2. Business Overview

2.1 What the company actually does

Occidental Petroleum is an international energy company whose dominant activity is the exploration, development, and production of crude oil, natural gas liquids (NGLs), and natural gas. Following the January 2026 divestiture of OxyChem, the business comprises three reporting activities, in descending order of value:

1. Oil & Gas (upstream) — the overwhelming majority of value and cash flow. Operations span:
   • The Permian Basin (Texas/New Mexico) — the core. OXY is the largest net acreage holder in the basin, operating two distinct businesses: Permian Resources (unconventional shale, ~1.5M net acres, ~6,300 gross wells) and Permian EOR (conventional CO₂ enhanced oil recovery, ~1.4M net acres, ~11,900 gross wells). Permian production was 786 Mboe/d in 2025, ≈55% of total (FY2025 10-K, pp. 1304–1308).
   • Rockies / DJ Basin and other US onshore.
   • Gulf of America (deepwater) — offshore conventional.
   • International — Algeria, Oman, and the UAE, operated largely under Production Sharing Contracts (PSCs); ~232 Mboe/d in 2025.
2. Midstream & Marketing — gathering, processing, transportation, CO₂ infrastructure, and commodity marketing/trading, including OXY’s interest in Western Midstream (WES).
3. Low Carbon Ventures (OLCV) / 1PointFive — the Direct Air Capture (DAC) and carbon-management venture, anchored by the STRATOS plant in Ector County, Texas.

2.2 How it makes money

OXY’s revenue is overwhelmingly the price of a barrel multiplied by the volume produced, minus the cost to lift it. The company sells oil, NGLs, and gas into Brent/WTI-referenced markets and takes the clearing price — it has no product differentiation and no pricing power. In FY2025, on a continuing-operations basis (OxyChem reclassified to discontinued operations), the company recorded net sales of $21,593M and total revenues of $22,075M (FY2025 10-K, p. 60). The income statement is dominated by two line items: oil & gas lease operating expense ($4,681M) and DD&A ($7,533M) — the latter a non-cash depletion charge that makes GAAP earnings look far smaller than cash flow.

The economics are liquids-driven. In 2025, realized oil tracked ~100% of WTI ($64.60/Bbl worldwide); NGLs realized only ~32% of WTI ($20.60/Bbl); and US natural gas realized just $1.58–1.65/Mcf — Permian/Waha gas is structurally weak and at times zero or negative at the hub. Oil is ~47% of proved reserves but the clear majority of revenue and essentially all of the margin.

2.3 The international and midstream pieces

The international portfolio (~232 Mboe/d, ~16% of volume) is economically distinct from the US shale business and frequently misunderstood. Algeria, Oman, and the UAE operate under Production Sharing Contracts (PSCs), in which OXY recovers costs and splits “profit oil” with the host government on a sliding scale. The structural consequence matters for a price spike like the current one: as the oil price rises, the government take rises and OXY’s incremental share falls — PSC economics mute the upside of a Hormuz-type windfall relative to a US working-interest barrel, and they carry political and fiscal-terms risk (the very region at the center of the current supply shock). These are lower-decline, longer-life conventional assets that diversify the production base but do not capture spot upside one-for-one. (Open question: exact PSC cost-recovery and profit-oil splits not pulled; flagged in Open Questions.)

Midstream & Marketing is a smaller, supporting cash-flow source: gathering/processing, the CO₂ pipeline network feeding the EOR business, OXY’s equity interest in Western Midstream (WES) (an MLP OXY does not consolidate at 100%), and a commodity marketing/trading desk. Midstream is also where the 1PointFive/STRATOS DAC capex (~$720M in 2025) is housed — so the segment blends genuine fee-based infrastructure value with the negative-carry DAC venture. In a sum-of-the-parts, the midstream/WES value is a few billion dollars, real but secondary to the upstream spine.

2.4 Revenue segmentation, customers, and recurrence

Customers are refiners, marketers, midstream counterparties, and traders — all of whom switch costlessly on price. There is no recurring-revenue character in the software/subscription sense; “recurrence” in an E&P comes only from the physical persistence of producing wells, which decline relentlessly (shale base declines ~35–45%/year), requiring perpetual reinvestment merely to hold output flat. This is the structural opposite of a high-quality recurring business: every barrel sold must be replaced with capital.

The post-OxyChem business is therefore more commodity-exposed and less diversified than the OXY of a year ago. The FY2025 10-K states it plainly: the company “is more exposed to fluctuations in the markets for oil, NGL and natural gas” following the OxyChem sale (FY2025 10-K, line 694). The chemicals ballast that historically dampened oil-price cyclicality is gone. (Note: OXY retained OxyChem’s legacy tort and environmental liabilities at close — those did not transfer to Berkshire.)

3. Industry Dynamics

3.1 The price-taker reality (the foundational structural fact)

Upstream crude oil is a globally fungible, exchange-priced commodity. An individual E&P — OXY included — has zero pricing power at the firm level. This single fact is the foundation of every conclusion in this analysis. In Greenwald’s framework there is no demand-side captivity (no switching costs, no brand, no network effect — a barrel is a barrel) and no firm-level supply advantage the marginal producer cannot eventually replicate. Differentiation is impossible; cost-curve position and scale economies in drilling are the entire game. Profit pools accrue disproportionately to the lowest-cost barrels — OPEC core producers (Saudi/UAE lifting costs in the low-single-digit $/bbl) and the best US shale acreage. US shale sits mid-cost (new-well breakevens ~$55–60 WTI), so US E&Ps are price-takers in the middle of the global cost curve: profitable above ~$60, squeezed below.

3.2 A live, regime-changing supply shock (June 2026)

Critical, time-sensitive fact. As of June 2026, there is an active Strait of Hormuz crisis — the IEA calls it the largest supply disruption in the history of the global oil market. Following US–Israeli strikes on Iran, the strait has been effectively closed to shipping since ~February 28, 2026 (EIA STEO, accessed 2026-06-04; corroborated multi-source).

• Crude shut-ins averaged ~10.5 Mb/d in April 2026 (peaking ~10.8 Mb/d in May). ~27% of seaborne crude transits Hormuz.
• Prices spiked: Brent ~$117/bbl in April 2026, ~$106 May–June, ~$95–97 the first week of June. WTI tracked near ~$95.
• EIA base case: Brent averages ~$95 in FY2026, then falls to ~$89 in 4Q26 and ~$79 in FY2027 as the strait reopens and Gulf supply recovers.

Interpretation (load-bearing for valuation): For an unhedged price-taker like OXY, this is a near-term cash-flow windfall — but it is a geopolitical spike, not a structural, demand-driven bull market. The forward curve and the EIA both point back toward a mid-cycle low-$60s–$70s WTI once Hormuz reopens. Every trailing or spot multiple computed on current cash flow understates the through-cycle multiple. The discipline this analysis imposes is to separate spot-windfall earnings (~$95–117 Brent) from mid-cycle/normalized earnings (~$65–70 WTI). Hormuz duration is the single biggest near-term swing on OXY’s cash flow — and it is entirely outside the company’s control, the defining feature of a price-taker.

3.3 The underlying (ex-war) regime is soft

Strip out the war premium and the structural 2026 picture is loosening:

• OPEC+ policy & spare capacity. The cartel — not US shale — sets the global floor/ceiling. OPEC+ fully unwound a 2.2 Mb/d cut tranche in 2025 and began releasing a further 1.65 Mb/d layer; only Saudi Arabia and the UAE hold meaningful spare capacity. This is paper supply waiting to return once Hormuz normalizes.
• Demand / energy transition. China — the multi-decade demand engine — is plateauing and is projected to peak ~2027, pressured by record EV sales (>20M globally in 2025) and gas-truck/rail substitution. The IEA estimates EVs displace ~5.4 Mb/d of demand by 2030; global demand plateaus ~105.5 Mb/d and may begin a small decline ~2030. This is the structural terminal-demand overhang.
• Inventories. Pre-crisis, the market was tipping toward oversupply (the bearish setup that produced the $58–65 WTI tape of late 2025). The Hormuz shock flipped this violently (EIA expects ~8.5 Mb/d of 2Q26 inventory draws), but the oversupply thesis likely reasserts post-crisis.

Mid-cycle gravity is the low-$60s–$70s Brent, with genuine downside risk if OPEC+ floods or demand disappoints.

3.4 The Permian is maturing

OXY’s core basin is past its prime-quality peak. Analysts estimate ~60% of Permian Tier-1 acreage is already drilled, leaving ~3.7 years of premium inventory at current drilling rates; operators are shifting to Tier-2/3 rock. Average oil productivity per well fell ~6% in 2025 (double-digit declines at some operators). The basin is holding output via efficiency (longer laterals, better completions) rather than more rigs (~241 active Permian rigs as of May 2026, well off peaks). Recurring constraints — negative/zero Waha gas pricing, produced-water disposal, and induced-seismicity curtailment zones — are rising structural costs that worsen as the basin ages. OXY bought top-tier Midland inventory (CrownRock) precisely as Tier-1 scarcity became the binding constraint; whether that was well-timed or overpaid is a capital-allocation question (Section 7), but structurally OXY’s resource depth is above peer-average even as the basin matures.

3.5 Capital-cycle position (Marathon lens)

US shale has shifted decisively from the 2010–2019 “growth-at-any-cost” over-investment phase into a capital-discipline / consolidation up-phase: 38 tracked E&Ps cut capex ~4% in 2025; average 2026 WTI planning prices fell to ~$59; majors are holding disciplined budgets despite political pressure to “drill, baby, drill.” A >$100B Permian M&A wave (ExxonMobil/Pioneer $64.5B; Chevron/Hess ~$60B; ConocoPhillips/Marathon $22.5B; Diamondback/Endeavor ~$26B; OXY/CrownRock ~$12B) has concentrated acreage in low-cost mega-operators. In Marathon’s framework, this is the good phase — capital is being withdrawn, supply growth restrained, rents concentrated in survivors — and it plausibly raises through-cycle ROIC if discipline holds. The skepticism: commodity-industry discipline is historically fragile, and a sustained high-price regime (exactly like the current Hormuz spike) is the classic trigger that has broken it before. The most durable enforcer of discipline here is geology (you cannot grow cheaply when Tier-1 rock is scarce); the most reversible is investor sentiment.

3.6 Policy

US policy currently amplifies the up-phase and is pro-OXY: an expansive 11th OCS leasing program (positive for Gulf of America deepwater), methane-rule rollbacks, and — critically — the One Big Beautiful Bill Act (OBBBA, signed July 4, 2025), which preserved and enhanced 45Q: the DAC credit holds at $180/tonne, and — new — CO₂ used for enhanced oil recovery now earns the same credit as dedicated storage. The 45Q EOR-parity change is directly favorable to OXY’s CO₂-EOR-plus-DAC model (Section 4.4). International PSC terms (Algeria/Oman/UAE) cut the other way: government take rises with price, muting the upside of a spike.

3.7 The CCUS / carbon-removal industry

Engineered carbon removal (DAC) is not yet a real, self-sustaining commercial market. It is propped up by the $180/t 45Q credit and a thin voluntary-offset market where a handful of deep-pocketed corporates pay $200–1,000/t for reputational/ESG reasons. Reported STRATOS capture costs are near ~$400/t against a $180/t credit — the economics do not close on subsidy alone; they require high-priced voluntary offtake and/or the CO₂-EOR monetization pathway. Competitors (Climeworks, Heirloom) are sub-scale and similarly subsidy-dependent.

3.8 Verdicts

Upstream oil & gas: structurally a poor-to-mediocre industry for durable excess returns. Zero firm-level pricing power; deep cyclicality dictated by OPEC+ and exogenous shocks; depleting assets requiring perpetual reinvestment; Tier-1 inventory exhaustion eroding resource quality; structural terminal-demand risk. The offset is a genuine — but fragile — capital-discipline up-phase. The current high-price windfall is cyclical, not structural; do not mistake the Hormuz spike for an improvement in industry quality.

CCUS / carbon removal: not yet an investable industry. Subsidy- and voluntary-offset-dependent, not cost-competitive. For OXY it is differentiated optionality, not an earnings engine.

4. Competitive Position

4.1 The moat screen (Greenwald)

Running OXY through the three genuine advantage types:

• (a) Supply / cost advantage — PARTIAL, and the only candidate. OXY’s cash lifting cost is low and improving ($8.94/Boe in 2025 vs. $9.75/$10.48 prior), driven by Permian scale and lower Oman energy costs. But a cost-leadership moat requires sitting on the left of the cost curve versus all comers, and independent sell-side coverage flags OXY’s remaining-inventory breakeven as among the highest in North American coverage — middle-to-right, not left. OXY is deep on resource but carries a heavier cost tail than Diamondback (FANG) and more leverage than EOG. Partial, contestable cost advantage; not cost leadership.
• (b) Demand / captivity — ABSENT. Buyers switch costlessly on price. Zero customer captivity.
• © Economies of scale (+ captivity) — ABSENT as a moat. OXY is large (1,434 Mboe/d), but ExxonMobil/Chevron/ConocoPhillips are larger and Midland pure-plays match or beat OXY on well-level cost. Permian share shifts with the rig count and M&A — there is no stable, share-protected oligopoly.

The company’s own 10-K concedes the business is “highly competitive,” that “market conditions significantly influence hydrocarbon pricing,” and that some competitors “are larger and better funded… [or] have greater access to capital” (FY2025 10-K, lines 516, 815). It was unhedged at 12/31/2025 — an explicit acceptance of full price-taker exposure.

4.2 The one genuine, narrow edge: CO₂-EOR

OXY’s CO₂ enhanced-oil-recovery franchise is real and hard to replicate: “34 active CO₂ floods, over 50 years of experience,” industry leadership in Permian CO₂ flooding, 1.4M net EOR acres, and 2.8 Bcf/d of CO₂ pipeline/processing infrastructure (FY2025 10-K, lines 1306–1308). CO₂ flooding can lift ultimate recovery 10–25% from legacy fields at low decline rates and modest sustaining capex — a stable, long-life cash annuity a pure shale player lacks, and an intangible/know-how plus sunk-infrastructure barrier competitors cannot quickly copy. Applying the moat test: this edge is tied to a financial outcome (a low-decline barrel base), so it is a modest, real differentiator. But it is small relative to the whole, does not insulate corporate ROIC from the oil price, and its economics still live or die on WTI. It is a quality differentiator, not a price-independent moat.

The economic mechanism is worth spelling out because it links to the carbon-capture strategy. In CO₂ flooding, OXY injects CO₂ into mature reservoirs to mobilize oil that primary and secondary recovery left behind, lifting ultimate recovery by an estimated 10–25%. Two features make it a quasi-annuity: the production declines slowly (these are decades-old fields, not 40%-first-year-decline shale wells), and the sustaining capital is modest once the CO₂ infrastructure is sunk. The barrier is the 2.8 Bcf/d of CO₂ pipelines, processing, and 50 years of subsurface know-how — a competitor cannot simply buy its way to an equivalent system. Crucially, this is also the bridge to the DAC thesis: captured atmospheric CO₂ can, in principle, be routed into the EOR floods, and under OBBBA’s new 45Q EOR-parity, that CO₂ now earns the same tax credit as dedicated geologic storage. So the EOR franchise is simultaneously OXY’s most durable conventional asset and the commercial rationale for 1PointFive. The tension (Section 4.4) is that “carbon removal” feeding more oil production is a narrative and accounting contradiction the market has not fully priced either way. Even granting all of this, the EOR edge raises asset quality, not pricing power — corporate ROIC still collapses when WTI falls, which is the test that matters.

4.3 What was sold: the OxyChem moat is gone

Pre-sale, OxyChem was the closest thing OXY had to a true Greenwald cost moat — US chlor-alkali/PVC benefiting from cheap domestic ethane/gas feedstock vs. naphtha-based global competitors, plus scale and integrated salt-dome assets, and counter-cyclical (often inversely correlated to oil) earnings. Its sale to Berkshire (closed January 2, 2026) means the portfolio’s single durable advantage has left, and OXY is now more of a pure price-taker with weaker through-cycle quality, even as the balance sheet is cleaner.

4.4 1PointFive / DAC: option, not moat

The STRATOS DAC plant (up to 500,000 t CO₂/yr, ~$1.3B cost, JV with BlackRock’s infrastructure fund, ~$550M of partner capital, operations expected to begin 2026) is best characterized as a subsidized real option with negative near-term economics. It consumes capital (~$720M of 2025 midstream capex was majority-STRATOS) and generates no material profit; its unit economics only work if 45Q stays at $180/t and capture cost falls toward ~$130–150/t and a voluntary CDR market scales — three contingent “ifs,” each outside OXY’s control, and the 10-K itself flags impairment risk (FY2025 10-K, lines 808–811). By the moat test, removing DAC tomorrow would improve current cash earnings — the opposite of a moat. That OXY brought in BlackRock to de-risk its own capital is itself a signal of how uncertain the standalone returns are. Treat DAC as out-of-the-money optionality with real ongoing carry, not a second business line.

4.5 Verdict — competitive position

Above-average assets, no durable moat. OXY’s differentiators — deep Permian inventory (16.5 Bboe total resource, ~70% Permian), falling LOE, and the hard-to-replicate CO₂-EOR base — confer above-average asset quality and durability, but none is a price-independent moat. Its remaining-inventory breakeven is among the highest in coverage, and it carries more financial leverage (including the $8.5B 8% preferred) than higher-quality peers (ConocoPhillips, EOG, Diamondback). Through-cycle ROIC/ROE are dictated by WTI, not by OXY — the defining feature of a no-moat commodity business. The Berkshire stake/warrants/preferred is a sponsorship/sentiment factor, not a business moat. On the moat and balance-sheet axes, OXY is lower-quality than COP, EOG, and FANG, comparable-to-better than Devon on inventory depth, and uniquely advantaged only in CO₂-EOR know-how.

5. Growth History and Forward Opportunities

5.1 Historical growth — acquisition-led, not organic

OXY’s production growth over the past several years has been driven by M&A, not organic outperformance. Total production rose from 1,223 Mboe/d (2023) → 1,327 (2024) → 1,434 (2025) — an ~8% YoY step in 2025 — but the 2024 jump was substantially the CrownRock acquisition (closed August 2024, ~170 Mboe/d added). Permian volumes grew 584 → 664 → 786 Mboe/d over the same span, again CrownRock-aided. This is acquired, debt-funded growth, not capital-efficient organic compounding.

On reserves, proved reserves moved 3,982 → 4,612 → 4,603 MMboe (2023–2025) — the 2024 jump was CrownRock; 2025 was roughly flat, with organic adds (~561 MMboe) replacing ~107% of production (523 MMboe) — adequate, not spectacular. The proved-developed share rose to 72% (from 69%), a higher-quality, more PDP-weighted book that needs less future capital to convert but offers a shorter reserve life (~8.8 years R/P). This is a mature, Permian-heavy asset base requiring sustained capex to hold production flat — not a long-life “treasure chest.”

5.2 Forward opportunities

• Permian inventory conversion. The largest lever. OXY claims 16.5 Bboe of total resource (70% Permian), with CrownRock adding >1,200 Midland locations management says break even below $40/bbl and a stated ~84% of resource below $50/bbl WTI (management figures — treat as hypothesis, given the independent flag that OXY’s remaining-inventory breakeven is the highest in coverage). The forward opportunity is real but price- and execution-dependent, and converts to value only at WTI above its breakeven.
• CO₂-EOR + 45Q EOR-parity. The OBBBA change letting EOR CO₂ earn the full 45Q credit is a genuine, OXY-specific tailwind that could improve EOR economics and partly subsidize the legacy floods.
• 1PointFive DAC. A wide-distribution call option (could be a real long-dated franchise if costs fall and policy holds; could be a write-off). Not a base-case growth engine.
• Gulf of America deepwater — supported by pro-production federal leasing.
• Deleveraging-into-buybacks. The most certain per-share lever is mechanical: once debt reaches ~$10B and the preferred constraint relaxes (post-2029), OXY can resume buybacks and shrink a currently-rising share count.

5.3 Verdict — growth quality

Low-to-medium quality. Headline production growth is largely acquired and debt-funded, not organic and capital-efficient; organic reserve replacement is merely adequate (~107%); the basin is maturing; and per-share growth has been negative on the share-count axis (count rising via warrant exercises while peers shrink theirs). The highest-conviction forward value is not new oil — it is balance-sheet repair converting into eventual capital return — which is gated by the preferred, not by FCF. This is not a growth story to underwrite as a strength.

6. Financial Quality

All figures continuing-operations basis (OxyChem in discontinued ops), reconciled to the FY2025 10-K and Q1 2026 10-Q. Cross-filing comparisons use the FY2025 10-K restated basis — note FY2024 net sales were $26,725M as originally reported (incl. OxyChem) vs. $22,019M restated.

6.1 Income statement (continuing ops, $M except per share)

The $1.35 continuing-ops diluted EPS is the run-rate anchor, not the $1.61 GAAP figure (which is flattered by the small disc-ops contribution). Net income to common is after the $679M annual preferred dividend (8% on the ~$8.49B Berkshire Series A face; FY2023’s $923M charge included $151M+ of redemption premiums on $1,661M of preferred retired that year). Q1 2026 net income of $3,359M is almost entirely the $3,123M OxyChem disposal gain (discontinued ops); continuing-ops income to common in Q1’26 was only ~$52M, reflecting a soft commodity quarter and elevated interest from accelerated debt paydown. One-time items to normalize: the OxyChem disc-ops gain (~$3.1B, Q1’26); a $925M FY2024 chemical impairment (in disc-ops); continuing-ops impairments ($60M/$356M/$209M FY25/24/23); asset-sale gains (+$263M FY25, +$522M FY23); and the recurring preferred drag.

6.2 Per-Boe unit economics (the heart of an E&P)

The 15% three-year decline in LOE/Boe is the single clearest piece of evidence of scale economics — but only on the cost side. Realized oil tracks ~100% of WTI (no marketing premium), NGLs realize ~32% of WTI, and US gas is economically marginal (~$1.58/Mcf, periodically negative at Waha). Derived metrics (independently computed, labeled assumption): organic F&D ~$10.9/Boe (FY2025 dev + exploration ÷ organic adds), an upstream cash netback of ~$48–50/Boe at FY2025 realized prices, and an organic recycle ratio of ~4.4x — strong on the organic measure, weaker (~2–3x) once CrownRock’s ~$12B acquisition cost is amortized over acquired reserves. Open question: management’s own F&D/recycle disclosure was not located in the 10-K; the figures above are independently derived. Verdict on unit economics: costs improve with scale; profitability does not — it is WTI-set.

6.3 Reserves

Proved reserves 4,603 MMboe (47% oil / 25% NGL / 28% gas), 72% developed, ~8.8-year reserve life. PV-10 (standardized measure) = $36,627M at YE2025 — down from $42,871M (YE2024) purely on a lower SEC price deck (~$64.42 trailing-average oil), underscoring how price-sensitive the asset value is. At a lower strip, PV-10 shrinks materially; at a higher strip, it expands. This $36.6B figure is the proved-reserve floor against which the ~$78B EV must be judged (Section 10).

6.4 Cash flow and free cash flow

Go-forward FCF should be anchored on the continuing-ops figure (~$3.2B at ~$65 WTI), since OxyChem’s ~$0.9B CFO is gone. Of 2025 capex, ~$5.6B was oil & gas and ~$0.7B midstream/LCV (STRATOS). The common dividend is $0.96/share (~$945M); the preferred is $679M; combined cash dividends $1,594M. Management cites a ~$51 WTI FCF breakeven — an IR/transcript figure not found verbatim in the 10-K; treat as hypothesis — though an independent sensitivity model lands near the same breakeven. Earnings quality is high: CFO (~$10.5B) runs ~4.4x net income on $7.5B of non-cash DD&A; no sign of net income outrunning cash; the OxyChem gain is correctly isolated. The caveat is purely that GAAP EPS is flattered by disc-ops — anchor on continuing ops.

6.5 Balance sheet and leverage (the key issue)

The de-levering is real and rapid: face debt $24.4B (YE2024) → $20.4B (YE2025) → ~$13.8B (March 2026, principal $13,757M), target ~$10B. The maturity wall is heavily back-end-loaded (only ~$24M due 2026, ~$48M 2027; ~$14.6B in 2030+), so there is no near-term refinancing cliff; interest expense is falling ($1,169M → $1,079M and dropping). On the senior-debt line, the balance sheet is now investment-grade-comfortable on a net-debt/EBITDA basis of ~1.1x ex-preferred by March 2026.

But the $8.5B Berkshire 8% preferred is hidden leverage. It is not in “total debt,” yet it behaves like expensive, near-permanent senior capital: $679M/year cash cost, cannot be voluntarily redeemed before August 2029, and a mandatory 10%-premium redemption trigger on common distributions above $4.00/share. Including it, “true” economic leverage is ~$20B+ and net-debt/EBITDA is ~1.9x. The senior debt is largely solved; the preferred is the unfinished, expensive, return-capping piece. Tangible book attributable to common is ~$28/share, so OXY at ~$58 trades ~2x tangible book.

6.6 Dilution / warrants

Shares outstanding ~986M (YE2025); diluted ~1,023M. Two warrant tranches: 30.4M @ $22 (deeply in-the-money, legacy) and the Berkshire warrant — 83.9M shares @ $59.59 (roughly at-the-money at ~$58; a persistent ~8.5% overhang, dilutive above strike). The share count drifted up in 2025 (~43.6M added via warrant exercises + plan issuance, $930M cash received), the opposite of peers shrinking their counts. Until the preferred is gone and the warrant clears, OXY cannot meaningfully shrink its share base. SBC is small for an E&P of this size; the warrant/preferred package is the real dilution and capital-return constraint.

6.7 Returns through the cycle

ROE on common (derived): ~6% FY2025 (continuing-ops ~5%) at mid-$60s oil, ~9% FY2024, ~17% FY2023, and >40% in 2022 at $94 WTI. This swing is the whole story: returns are entirely WTI-dependent, currently below cost of equity, and the 2022 peak was a price spike, not a structural improvement. The CrownRock-enlarged base improved scale/cost but diluted returns near-term because it was largely debt-funded at a cyclical cost peak.

6.8 Verdict — financial quality

(a) Do economics improve with scale? Partially yes on cost (LOE −15%, proved-developed up to 72%, Permian 55% of volume), but no on profitability/returns — ROE/ROIC are WTI-set and currently below cost of capital. (b) Is the balance sheet de-risked? Materially yes on senior debt; no on the preferred, which remains an expensive, near-permanent claim that caps capital returns until ~2029. © Earnings quality? High — CFO runs ~4.4x net income on non-cash DD&A, no red flags. The franchise generates real cash at mid-$60s oil; the GAAP earnings are simply DD&A-suppressed and preferred-skimmed.

7. Capital Allocation

7.1 The M&A scorecard

Anadarko (2019, ~$55B) — the defining, near-fatal deal. OXY won a bidding war against Chevron (which walked away with a $1B breakup fee — a tell that the far-larger CVX thought the price too high), financing the deal with the most expensive capital available: a $10B Berkshire 8% perpetual preferred, a bridge loan, and a pre-sold divestiture of Anadarko’s international assets to TotalEnergies. When COVID collapsed oil in 2020, OXY posted a -$14.8B net loss, took massive impairments, and cut the common dividend ~86% (from $0.79 to $0.11/quarter, ultimately to $0.01). Equity holders were nearly wiped; Berkshire’s preferred sat senior and unscathed. This is a textbook top-of-cycle, debt-and-ego-funded acquisition — value-destructive as executed, and the source of the preferred handcuff that still binds seven years later.

CrownRock (August 2024, $12.4B = $9.4B cash + 29.6M shares + $1.2B assumed debt). A smaller, better-timed, partly stock-funded Midland bolt-on that added ~170 Mboe/d of top-tier inventory and helped drive LOE lower. Defensible strategically — but it again added ~$9B+ of debt at mid-$70s WTI just as peers were de-levering and buying back stock, re-creating the leverage problem OXY had spent four years escaping. The concern is the repeated pattern, not the single deal.

OxyChem sale (closed January 2, 2026, $9.7B all-cash to Berkshire, ~$3.2B gain). A rational forced sale: management monetized its steadiest, most counter-cyclical, arguably-moaty business to repair a balance sheet the prior deals had stretched, routing all proceeds to debt. On chemicals-peer comps (~5–7x EV/EBITDA), $9.7B on OxyChem’s estimated ~$1.0–1.5B mid-cycle EBITDA is a fair (~6–9x) but not premium price for the seller — and arguably a good price for Berkshire given the asset quality. That the buyer is the same counterparty holding the expensive preferred is notable: Buffett extracted a clean, recession-resistant cash-flow asset at an undemanding price while OXY remains burdened by his 8% preferred. This is balance-sheet triage — selling the best business to pay for the worst deal — not value creation.

7.2 Debt management — recovery, not stewardship

The deleveraging ($24.4B → ~$13.8B → ~$10B target) is real and de-risking, but it is digging out of a self-inflicted hole created by Anadarko and re-inflated by CrownRock, funded substantially by selling assets (OxyChem, divestitures) rather than purely organic FCF. The destination is good; the journey is the indictment. Management is a competent fixer of a problem it created. Credit ratings reflect the in-between state: as of YE2025 OXY is split-rated — Baa3 (Moody’s, IG) and BBB- (Fitch, IG), but BB+ (S&P, one notch below IG).

7.3 The Berkshire preferred — the central constraint

84,897 shares of Series A Cumulative Perpetual Preferred (down from 100,000; OXY redeemed $1,661M face in 2023), $100,000 face (~$8.49B), $105,000 liquidation preference (~$8.91B), 8% (~$679M/yr). The mechanism: before August 2029, a mandatory redemption obligates OXY to redeem preferred at a 10% premium, dollar-for-dollar, for every dollar of common distributions (dividends + buybacks) above $4.00/share trailing-12-month. After August 2029, OXY may voluntarily redeem at a 5% premium. This is precisely why OXY ran zero buybacks in 2025 and keeps the dividend at $0.96 — management is deliberately staying under the $4.00/share threshold to avoid triggering forced, premium-priced preferred redemptions while it prioritizes senior-debt paydown. Fully clearing the ~$8.5B face would cost ~$9.3B pre-2029 (10% premium) or ~$8.9B after. Any thesis on OXY shareholder returns is gated by this instrument, not by FCF.

7.4 Shareholder returns

Dividend history is a fragility flag: ~$3.16/yr (2019) → cut ~86%+ in 2020 → slow rebuild → $0.72 (2023) → $0.96 (2025) → raised >8% in early 2026. Buybacks: $1,798M (2023), $27M (2024), zero (2025). While IG-balance-sheet peers (EOG, CVX, XOM) spent 2023–25 aggressively shrinking share counts, OXY’s count rose. Per-share compounding via repurchase is structurally on hold until debt hits ~$10B and the preferred constraint relaxes. This is not a capital-return story today.

7.5 Insider behavior — Berkshire is the signal (heavily caveated)

Berkshire’s open-market common purchases (2022–2024, code P) lifted its stake to ~265M shares (~26.6% as of March 31, 2026; the often-cited “~28%” was Berkshire’s percentage in early 2025 — the same share count is now a lower percentage because OXY’s count grew via dilution, not because Berkshire sold). The last open-market purchase was ~February 7, 2025 — none in the 16 months since. The price tell is informative: Buffett’s largest tranches clustered in the mid-$40s (Dec 2024 ~$45.55; Feb 2025 ~$46.82); he bought through the high-$50s in 2023–24 but stopped as the stock recovered toward/above the ~$59.59 warrant strike. The one genuine officer/director conviction buy was director William Klesse, 5,000 shares @ $38.98 (Dec 2025) — the same “buy the $40s” pattern. Routine officer Form 4s are vesting/withholding (S/A/M/F), with no discretionary buy cluster. Caveat: Berkshire is conflicted/advantaged — its real edge is the 8% preferred + warrant + the OxyChem purchase, not the common; its buys are a heavily-caveated signal, not a clean endorsement.

7.6 Compensation & incentives — a genuine positive

From the 2026 proxy: CEO (Hollub) total comp was ~$18.06M (2025), ~90% variable, with compensation actually paid swinging hard with TSR ($11.3M/$4.3M/$15.0M 2025/24/23 — genuine pay-for-performance sensitivity). Critically, the metrics are return- and cash-based, not production-growth-based: long-term incentive = 30% CROCE PSU + 30% relative/absolute TSR PSU + 40% RSU; the annual cash incentive = 70% financial (with FCF-before-working-capital replacing CROCE for 2025 per shareholder feedback) + 20% strategic + 10% sustainability. Say-on-pay support exceeded 94% at every meeting 2021–2025. This avoids the classic “paid to drill regardless of returns” trap and is atypically well-aligned for the sector. Caveats: no explicit debt-reduction metric despite that being the story; and pay quantum stayed high (~$18M flat) even as OXY’s 3-year TSR ($252) modestly trailed the peer group ($268).

7.7 Verdict — capital allocation

Mixed, tilting negative on the record, competent on the recent cleanup. The defining act (Anadarko) destroyed enormous value and created the preferred overhang; CrownRock repeated the debt-funded pattern; the recent moves (rapid deleveraging, OxyChem monetization, return discipline) are the right actions but are a skilled fixer undoing a self-inflicted wound — partly by selling the best business to the same counterparty holding the expensive preferred. The return-based incentive design and >94% say-on-pay are genuine positives. Net: this is not a capital-allocation franchise to underwrite as a strength. The classic skepticism toward commodity managements “buying high and over-investing” is squarely validated by the Anadarko/CrownRock pattern.

8. Changes and Headwinds — Last Two Years

8.1 The material-event timeline (2023–2026)

A review of the trailing 36-month SEC filing corpus (50 8-Ks, 9 10-Qs, 3 10-Ks, 3 proxies, 105 Form 4s) identifies three thesis-defining events and a supporting cast:

• CrownRock acquisition — announced Dec 2023, closed Aug 1, 2024 (~$12.4B; the re-levering, Permian-scale add).
• OxyChem sale to Berkshire — announced Oct 2, 2025, closed Jan 2, 2026 ($9.7B all-cash; the deleveraging + pure-play-E&P pivot).
• CEO succession — Richard A. Jackson (promoted COO Oct 2025) became President & CEO effective June 1, 2026; Vicki Hollub retired from the CEO role and remains on the Board. As of this writing (June 4, 2026), the transition is effective, not pending — Jackson is the sitting CEO, a leadership change worth monitoring for any strategic shift.
• Supporting machinery: a $4.7B term loan and amended revolver (CrownRock financing); the March 2025 exercise of the $22-strike legacy warrants (~$930M of cash in); and February/March 2026 high-coupon note tenders (a Q2’26 debt-extinguishment gain/loss is pending).

8.2 Macro headwind/tailwind

The Strait of Hormuz crisis (Section 3.2) is the dominant recent change — a near-term tailwind to cash flow (Brent ~$95–117) but a transient, geopolitical one. The underlying structural picture (OPEC+ paper capacity, peaking Chinese demand, EV penetration, a maturing Permian) is a headwind that reasserts once the strait reopens.

8.3 News-flow check

A scan of curated, AI-scored recent news returned no scored articles for OXY across importance tiers at the time of writing — a quiet tape, not a thesis input here. A quiet tape is a valid finding; the recent-events narrative above is built from primary filings and EIA/IEA data.

8.4 Verdict

The last two years net to a structurally simpler, more debt-light, but more commodity-cyclical and less-diversified OXY, under brand-new CEO leadership, riding a transient oil windfall. The changes strengthen the balance sheet and weaken the business-quality/diversification profile — and leave the preferred overhang and the WTI dependence fully intact.

9. Risk Analysis

Highest-conviction risks: #1 (oil reversion) and #2 (preferred cap) — both are active now, not speculative, and together define the asymmetry: limited cushion if oil reverts, capped returns even if it doesn’t.

10. Valuation Discussion (embedded expectations — no price target)

10.1 The EV build (the preferred is the swing item)

Common market cap ~$57.8B (986M shares × ~$58.67; ~$60B fully diluted) + net debt ~$11.8B (March 2026 face $13.8B − ~$2B cash) + the $8.5B Berkshire preferred = ~$78.1B economically-correct EV. Critical caveat: most screens (EV/EBITDA ~7.5x) exclude the preferred. Added back correctly, EV/EBITDAX is ~7.4x (ex-preferred ~6.6x) — the preferred hides ~0.8 turns. Any peer comparison must capitalize the preferred, or OXY looks ~10–12% cheaper than it economically is.

10.2 Comp table (public market-data aggregators, 2026-06-04; unofficial, reconcile)

*EV/EBITDA per public aggregators; OXY’s excludes the $8.5B preferred — add ~0.8x.

Read: OXY’s 79x trailing / 14.7x forward P/E is the richest of the independent set — but P/E is the wrong lens: net income is suppressed by $7.5B non-cash DD&A and the $679M preferred dividend, making EPS a tiny denominator. On the right lens (preferred-adjusted EV/EBITDAX), OXY at ~7.4x sits at the high end of the independents (DVN 5.3x, APA 3.6x cheapest; EOG 6.3x; COP 6.9x; FANG 7.6x) and well below integrated majors. OXY is not cheap versus lower-leverage, higher-quality independents once the preferred is capitalized — the opposite of a value screen. It does not screen rich on EV/boe of production (~$54.5k) or EV/proved-boe (~$17.0), which are mid-pack and reflect a real, large, liquids-weighted asset base. The premium is concentrated in the equity line and reflects inventory depth + de-levering catalyst + Berkshire halo + DAC option.

10.3 Embedded-expectations analysis (the centerpiece)

EV (incl. preferred) ~$78B vs. proved-reserve PV-10 of $36.6B → the market pays ~$41–44B above proved-reserve value. Decomposing that premium: (a) unproved/unbooked Permian inventory — the largest piece (the ~12 Bboe of unproved resource beyond the 4,603 MMboe proved), real but price- and execution-dependent, and on OXY’s highest-in-coverage breakeven; (b) a mid-cycle oil price above the ~$64 SEC deck; © midstream/WES (a few $B); (d) the DAC option (near-zero base value); (e) de-levering + Berkshire-halo re-rating optionality.

Reverse-engineered, justifying ~$78B EV at a ~6.5–7x mid-cycle EV/EBITDAX requires the market to underwrite roughly $11–12B of mid-cycle (not spot) EBITDA — implying a sustained mid-cycle WTI of roughly $68–75. Conclusion: at ~$58–60, the market is not pricing the $95–117 spike as permanent (sensible), but it is underwriting a constructive mid-cycle (~$70+ WTI), continued de-levering to ~$10B, successful conversion of unproved Permian inventory at acceptable breakevens, and some DAC option value. The price is mid-cycle-fair-to-slightly-full — it bakes in a benign oil regime and flawless execution; it does not embed a bearish $50–60 reversion. The asymmetry: thin margin of safety if oil reverts, meaningful upside only if the windfall persists or mid-cycle settles structurally higher.

10.4 Scenario analysis (explicit WTI; independently derived, ~$220M after-tax FCF per $1 WTI)

The equity is a levered, unhedged call on WTI: post-preferred FCF yield swings from negative at $50 to ~16% at $95. The preferred is the break point in the down-cases — at $55 WTI, ~$1.0B FCF cannot cover the $679M preferred + $945M dividend, forcing asset sales, capex cuts, or balance-sheet stress. The base case (~$65–70) is roughly where the stock is priced — a fair (not cheap) ~5.5–7.5% FCF yield for a no-moat, levered commodity E&P; lower-leverage peers offer comparable or better FCF yields with less risk.

10.5 NAV / sum-of-the-parts (range, not a point)

The SOTP brackets the current ~$58–60 price at the high (constructive-oil) end and well below it at the bearish-oil end — consistent with the embedded-expectations read that the stock is priced for a benign mid-cycle. The single biggest swing factor is oil flexing PV-10 + unproved inventory; DAC is a rounding error at the low end. The gap between tangible book (~$28/sh) and the constructive NAV (~$59/sh) is entirely unproved inventory + mid-cycle-price optionality.

10.6 The preferred drag, and the Buffett anchor

The preferred is a triple drag on common value: a cash drag ($679M ≈ 21% of FY25 continuing FCF), a capital-return cap (the $4.00/share trigger blocked all 2025 buybacks while the share count rose), and a redemption premium (~$0.4–0.8B that leaves common holders when it clears). Any FCF-yield or EV/EBITDA comparison to debt-light peers must dock OXY for this.

The Buffett anchor: the $59.59 warrant strike is a soft structural ceiling (above it Berkshire is incentivized to exercise and dilute ~8.5%), and Berkshire’s own cash-buying stopped right around it — aggressive accumulation in the low-$40s, tapering through the high-$50s, no purchase since Feb 2025. At ~$58–60 the stock trades at the top of the most patient, structurally-advantaged value buyer’s revealed range, and at the warrant strike. This corroborates “mid-cycle-fair-to-full, not cheap.” (Caveat: Berkshire is conflicted — the common buys are a heavily-caveated signal, not a clean endorsement.)

10.7 What the market is pricing correctly vs. incorrectly

Likely correct: that the Hormuz spike is transient; that senior de-levering to ~$10B is on track; that OXY has deep Permian inventory and falling LOE; that the OxyChem sale was a fair balance-sheet repair. Likely under-appreciated: the preferred drag that screens hide (preferred-adjusted EV/EBITDAX is full, not a discount); that OXY’s highest-in-coverage breakeven makes its ~$41–44B premium-to-PV-10 more price-dependent than peers’; that the embedded ~$70+ mid-cycle WTI may be optimistic versus the structural pull to the low-$60s; and that DAC is negative-carry optionality, not value.

11. Variant Perception

Consensus view: OXY is a de-levering Permian giant with deep inventory, Berkshire backing, an improving balance sheet, and free DAC/carbon-capture optionality — a quality large-cap energy compounder riding an oil windfall.

The strongest bull case: Oil settles structurally higher than the EIA mid-cycle (Hormuz persists, OPEC+ discipline holds, or transition is slower than feared); OXY de-levers to ~$10B, begins retiring the preferred and buying back its (currently rising) share count; CrownRock’s sub-$40 Midland inventory converts as advertised; 45Q EOR-parity and a maturing CDR market turn 1PointFive from negative-carry into a genuine second leg; and the Berkshire halo + scarcity of large-cap liquids-weighted producers sustains a premium multiple. In a $80+ world, post-preferred FCF yield is ~11–16% and the equity is a high-beta winner.

The strongest bear case: OXY is a levered, no-moat, highest-breakeven price-taker priced for a benign oil regime. Once Hormuz reopens, WTI reverts toward the $50s–low-$60s (OPEC+ paper capacity, peaking China demand, EV penetration); at $55, FCF fails to cover the preferred + dividend, de-levering stalls, and the senior preferred squeezes the common. The current FCF is windfall-inflated, the multiple is full once the preferred is capitalized, the share count is rising, returns are below cost of capital at mid-cycle, and the company just sold its only moaty business to the same counterparty that holds its most expensive liability. The Permian is maturing into OXY’s highest-cost remaining inventory.

The 3–5 assumptions that matter most: (1) mid-cycle WTI ($55 bear vs. $70+ bull) — by far the dominant variable; (2) whether unproved Permian inventory converts at OXY’s high breakeven; (3) de-lever-to-$10B and preferred-retirement timing; (4) DAC/45Q economics and durability; (5) Hormuz duration.

What would falsify each side: The bull is falsified by a sustained sub-$55 WTI print post-Hormuz with stalled de-levering and an uncovered preferred. The bear is falsified by either a durable structurally-higher oil regime or a credible, oil-uncorrelated re-rating (STRATOS proving sub-$200/t economics with firm above-cost offtake) that adds value the bear case assigns to zero.

12. Fact vs. Interpretation Table

13. Open Questions

1. Management’s exact stated FCF-breakeven WTI (~$51?) and the per-$1-WTI FCF sensitivity — not disclosed verbatim in the 10-K; verify against the Q4’25/Q1’26 earnings transcript.
2. Upstream-only DD&A/Boe and management’s own F&D cost/recycle ratio — derived here; confirm against the IR deck.
3. OxyChem sale-price fairness — was $9.7B (~6–9x est. EBITDA) a fair arm’s-length price or an undemanding transfer to a 26.6% related-party/preferred holder? Verify OxyChem standalone EBITDA from the deal release.
4. STRATOS realized capture cost per tonne at startup (Q2 2026) and the fraction of nameplate under firm above-cost offtake — the key DAC falsification test.
5. Berkshire’s current ownership cap / standstill terms (FERC ~25% vs. up-to-50% approval) — verify against the latest 13D/A.
6. International PSC fiscal terms (Algeria/Oman/UAE) and how government-take scales with the current price spike — not pulled.
7. Pending Q2’26 debt-extinguishment gain/loss from the Feb/Mar 2026 note tenders, and retained-vs-transferred legacy environmental liabilities post-OxyChem.
8. Strategic direction under the new CEO (Jackson) — continuity vs. change in capital-return, DAC, and M&A posture.

14. What Must Be True

Bull case — what must be true

• Mid-cycle WTI holds ~$70+ (not a reversion to the $50s) — the dominant assumption.
• OXY de-levers to ~$10B and then begins retiring the preferred and buying back stock, reversing the rising share count.
• Unproved Permian inventory converts to value at OXY’s (high) breakeven without a price collapse.
• 45Q survives and DAC costs fall, turning 1PointFive into a real, value-additive second leg rather than a capital sink.
• Falsification test: a sustained sub-$55 WTI print for several quarters post-Hormuz, with stalled de-levering and an uncovered preferred + dividend — would break the bull case decisively.

Bear case — what must be true

• Oil reverts to the $50s–low-$60s once Hormuz reopens (EIA base case ~$79 Brent by 2027), exposing the windfall-inflated current FCF.
• The preferred cap continues to suppress per-share returns; the share count keeps drifting up.
• The market continues to mis-capitalize the preferred (treating the stock as cheaper than it is) until a price reset forces re-rating.
• Falsification test: either a durable, structurally-higher oil regime (Hormuz persists / OPEC+ discipline holds / transition stalls) or a credible oil-uncorrelated re-rating (STRATOS sub-$200/t with firm offtake) — either would falsify the “fully-priced, no offsetting value” bear thesis.

15. Source Appendix

The full, organized source list — primary SEC filings (FY2023–FY2025 10-Ks, Q1’26 10-Q, 2024–2026 proxies, the 36-month 8-K and Form 4 corpus), company press releases, EIA/IEA data, and secondary industry/news sources — is provided in the Source Appendix below.

Key primary sources: OXY FY2025 Form 10-K (filed 2026-02-18); OXY Q1 2026 Form 10-Q (filed 2026-05-05); OXY FY2024 Form 10-K (filed 2025-02-18); OXY 2026 DEF 14A (filed 2026-03-19); SEC Form 4 corpus (CIK 0000797468); EIA Short-Term Energy Outlook (accessed 2026-06-04); IEA Oil Market Report (May 2026). Quantitative cross-checks via SEC EDGAR XBRL and public market-data aggregators (unofficial, reconciled to filings).

No BUY/SELL recommendation or price target appears anywhere in Sections 1–15; the single position taken in this document is the clearly-labeled Claude’s Take block at the top, which is the author’s own view.

Appendix A — Diligence Questionnaire

Occidental Petroleum Corporation (NYSE: OXY) · 2026-06-04 Supplemental to the main analysis. Fact/Interpretation/Assumption labels applied where material. No BUY/SELL, no price target.

General

What thoughtful questions have other investors asked about this company? The recurring institutional questions are: (1) Is the Anadarko leverage finally fixed? — yes on senior debt (~$13.8B → ~$10B target), no on the $8.5B preferred. (2) What is Buffett really doing? — Berkshire built to ~26.6%, holds the 8% preferred + 83.9M warrants @ $59.59, bought OxyChem, and stopped buying common in Feb 2025. (3) Is the DAC/1PointFive bet real or a money pit? — currently negative-carry optionality (STRATOS ~$400/t vs $180/t 45Q). (4) When do buybacks resume? — gated by the $10B debt target and the preferred’s $4.00/share trigger, not by FCF. (5) Was selling the moaty chemicals business to cut debt the right call? — balance-sheet triage, defensible but revealing. (6) Is OXY’s Permian inventory as good as peers’? — deep on resource, but highest remaining-inventory breakeven in coverage.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Reported/spot earnings are temporarily elevated by the Strait of Hormuz windfall (Brent ~$95–117 vs. an EIA mid-cycle pull toward ~$79 by 2027) — so above mid-cycle now, but FY2025’s $1.35 continuing-ops EPS was struck at a soft ~$65 WTI. Through-cycle earnings are violently variable: net income $13.3B (2022, $94 WTI) vs. $4.70B (2023) vs. -$14.8B (2020 crash).

Internal actions or external environment? Overwhelmingly external. Returns are dictated by WTI. Internal actions move costs (LOE −15% over three years) and the balance sheet, but not the price that sets ~100% of the revenue line.

How stable are revenues? Unstable — a price-taker on a globally fungible commodity, fully unhedged at YE2025.

Outlook for products/services? Market size? Global oil demand ~104 Mb/d, plateauing ~105.5 Mb/d by ~2030, with China demand peaking ~2027 and EVs displacing ~5.4 Mb/d by 2030. The end market is large but structurally mature-to-declining long-term, international, and cyclical. The carbon-removal market OXY is building (DAC) is nascent and subsidy-dependent.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Less fragmented (a >$100B consolidation wave concentrated acreage in low-cost mega-operators — structurally healthier), but no less of a price-taking commodity at the firm level.

How profitable (ROIC/ROE)? Fact/Interpretation: WTI-determined and currently sub-cost-of-capital — ROE ~6% on common at mid-$60s oil, vs. >40% at $94 in 2022. Post-tax ROIC mid-single-digits at mid-cycle.

How profitable is the industry — competitors, barriers to entry? A poor-to-mediocre industry for durable excess returns: zero pricing power, perpetual reinvestment against ~35–45%/yr shale declines, Tier-1 exhaustion. Barriers are capital and geology (acreage, scale), not a moat — anyone with capital and acreage competes.

Can the business be easily understood? Yes — price × volume − lifting cost, plus a balance sheet and a preferred overhang. The DAC venture and the preferred mechanics are the only genuinely complex pieces.

Undermined by foreign low-cost labor? Not labor — but undermined by foreign low-cost barrels (OPEC core lifting costs in the low-single-digit $/bbl set the global price OXY must accept).

Do brands matter? No. A barrel is a barrel.

Nature of competition / switching costs / barriers to entry? Competition is on cost-curve position and capital access. Customer switching costs are zero. Barriers to entry are capital intensity and Tier-1 acreage scarcity — real but not a firm-level moat. The one genuine, narrow edge is the CO₂-EOR franchise (50+ years, 1.4M acres, 2.8 Bcf/d CO₂ infrastructure) — a low-decline annuity that is hard to replicate but small and still WTI-dependent.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — unproved/unbooked Permian inventory (the ~12 Bboe beyond the 4,603 MMboe proved). PV-10 of proved reserves is $36.6B; the market pays ~$78B EV, the ~$41–44B gap being mostly unbooked inventory + mid-cycle-price optionality. This is the central valuation question — real value, but price- and execution-dependent.

Off-balance-sheet liabilities? Assumption/Open Question: asset-retirement obligations, operating leases, and — notably — OxyChem legacy environmental/tort liabilities that OXY retained at the January 2026 close (they did not transfer to Berkshire), plus Anadarko-legacy environmental exposures. The $8.5B 8% preferred is a quasi-liability that sits outside “total debt” but is senior to common.

How conservative is the accounting? Reasonably conservative — earnings quality is high (CFO ~4.4x net income on non-cash DD&A; the OxyChem gain correctly isolated in discontinued ops). DD&A suppresses GAAP earnings rather than flattering them.

How CapEx-hungry? Very. ~$6.4B/yr of capex (~$5.6B upstream) is required just to hold ~1.43 Mboe/d roughly flat against steep decline rates. This is a capital-intensive, reinvestment-heavy business.

Capital Allocation & Management

How much FCF, and how is it used? ~$3.2B continuing-ops FCF at ~$65 WTI. 2025 priority was debt paydown (zero buybacks); secondary was a modest, growing dividend ($0.96). Philosophy: de-lever to ~$10B principal, then shift to buybacks/preferred retirement — gated by the preferred’s $4.00/share trigger.

Recent significant acquisitions? CrownRock ($12.4B, Aug 2024, Permian) — debt-funded; and the divestiture of OxyChem ($9.7B, Jan 2026). The defining historical deal is Anadarko ($55B, 2019) — value-destructive as executed.

Buying back shares? No — zero in 2025; the share count is rising via warrant exercises. The opposite of peers (EOG/CVX/XOM shrinking counts).

Issuing large amounts of new shares to insiders? SBC is small for the size. The real dilution is the 83.9M-share Berkshire warrant @ $59.59 and warrant exercises — a structural ~8.5% overhang, not insider grants.

Director/management compensation? CEO comp ~$18M, ~90% variable, on return/cash metrics (CROCE, FCF-before-WC, relative TSR) — not production growth — with >94% say-on-pay. A genuine positive, atypical for the sector.

Motivations of management? Incentives point to per-unit returns and capital discipline, which is good. The countervailing history: the Anadarko bidding-war “win” suggests a prior willingness to pursue scale/ego at the top of the cycle. New CEO Richard A. Jackson (eff. June 1, 2026) — strategic motivation under new leadership is unproven.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a standard US C-corp common stock (Form 1099, not K-1). (Note: OXY’s affiliate Western Midstream, WES, is an MLP, but OXY common itself is not.)

Dividend policy? Modest and rebuilt-from-a-cut: $0.96/yr (2025), raised >8% in early 2026, after an ~86% cut in 2020. ~1.7% yield. Constrained by the preferred trigger.

How profitable is the business? WTI-dependent; sub-cost-of-capital ROE (~6%) at mid-$60s oil; strongly cash-generative but DD&A- and preferred-skimmed at the GAAP line.

Net income diverging from cash from operations? Yes, favorably and normally — CFO (~$10.5B) runs ~4.4x net income on $7.5B non-cash DD&A. No red flag; this is the expected shape for a depletion-heavy E&P.

Risks & Downside

What would cause the stock to decline? A WTI reversion to the $50s once Hormuz reopens (the base-case structural pull); stalled de-levering; a forced/uncovered preferred + dividend at sub-$55 oil; a DAC impairment; or simple multiple compression from the current full preferred-adjusted level.

Risk of catastrophic loss? Low-to-moderate. A diversified, hard-asset, IG-trending producer — but 2020 proved the tail is non-zero: a price crash combined with high leverage produced a -$14.8B loss and an ~86% dividend cut. The senior balance sheet is far healthier now, which reduces (not eliminates) that tail.

Chance of total loss? Remote, barring a sustained price collapse layered on re-leveraging. The preferred sits senior to common, so in a severe downside the common bears disproportionate pain while Berkshire’s preferred is protected.

Recent News & Events

Has the business environment changed recently? Yes, materially: (1) the Strait of Hormuz supply shock (Feb 2026–) spiking oil — a transient cash-flow tailwind; (2) OxyChem sold to Berkshire (closed Jan 2, 2026) — a structurally simpler, more commodity-exposed company; (3) a new CEO (Jackson, eff. June 1, 2026); (4) 45Q EOR-parity under OBBBA (mid-2025) — a DAC/EOR tailwind.

Significant acquisitions/divestitures? CrownRock in, OxyChem out (see above).

Recent change in accounting policies? OxyChem reclassified to discontinued operations across all periods in the FY2025 10-K — a presentation change that shrinks reported “net sales” (FY2024 $26.7B → $22.0B restated); use one basis consistently.

Recent changes — new markets, facilities, management? STRATOS DAC plant nearing startup (Q2 2026); CrownRock-enlarged Permian footprint; new CEO; expanded Gulf of America leasing access. (A scan of curated AI-scored news returned no scored OXY articles at writing — a quiet tape; the timeline above is built from primary filings and EIA/IEA data.)

Frameworks applied: Greenwald — only candidate moat is a cost advantage, and it is middling (highest-in-coverage breakeven); no demand captivity or scale-network moat. Marathon capital-cycle — US shale is in a fragile capital-discipline up-phase; geology (Tier-1 scarcity) enforces discipline more durably than investor sentiment; a sustained war premium is the classic trigger that breaks it. Where the generic metric doesn’t fit (e.g., “brands”), the sector-appropriate analog is given.

Appendix B — Source Appendix

Occidental Petroleum Corporation (NYSE: OXY) All sources accessed/verified 2026-06-04.

Sources are grouped by type. Primary sources (SEC filings, company press releases, regulator data) take precedence over secondary (market data, trade press, industry research).

PRIMARY — SEC Filings (Occidental, CIK 0000797468)

Annual reports (Form 10-K)

• OXY FY2025 Form 10-K, filed 2026-02-18 — the spine of the report. Key items verified verbatim: Debt Ratings (Baa3/BBB-/BB+, p.83); LOE/Boe $8.94/$9.75/$10.48 (MD&A p.38); standardized measure/PV-10 $36,627M (p.119); proved reserves 4,603 MMboe (pp.6/29); OxyChem Transaction ($9.7B, closed 2026-01-02, ~$3.2B est. gain, discontinued ops); Series A preferred note (84,897 shares; $100k face/$105k liq pref; 8%; $4.00/sh trailing-12m trigger; 10% mandatory-redemption premium; no voluntary redemption pre-Aug 2029) pp.82-83; warrant glossary (Berkshire Warrant $59.59 strike; Common Stock Warrants “OXY.WS” $22.00 strike). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000797468&type=10-K
• OXY FY2024 Form 10-K, filed 2025-02-18. Used for the as-originally-reported (pre-OxyChem-restatement) income statement and the CrownRock acquisition ($12.4B; $9.4B cash + 29.6M shares + $1.2B assumed debt).
• OXY FY2023 Form 10-K, filed 2024-02-14.

Quarterly reports (Form 10-Q)

• OXY Q1 2026 Form 10-Q, filed 2026-05-05. OxyChem disposal gain $3,123M (disc-ops); principal/face debt $13,757M at 2026-03-31; continuing-ops income $236M.
• OXY Q3 2025 10-Q (2025-11-10), Q2 2025 (2025-08-06), Q1 2025 (2025-05-07), plus FY2023-24 quarters.

Proxy statements (Form DEF 14A)

• OXY 2026 DEF 14A, filed 2026-03-19. CEO comp (Hollub SCT $18.06M 2025); Pay-vs-Performance (CAP, TSR $252 vs peer $268, CROCE 19%/21%); LTI 30% CROCE / 30% TSR / 40% RSU; ACI metrics (FCF-before-WC); Say-on-Pay >94% (2021-2025).
• OXY 2025 DEF 14A (2025-03-20); OXY 2024 DEF 14A (2024-03-21).

Material-event reports (Form 8-K) — thesis-defining items

• OxyChem sale ANNOUNCED, 8-K filed 2025-10-02 (Item 7.01, joint OXY/Berkshire release + deck).
• OxyChem definitive PSA, 8-K filed 2025-10-03 (Item 1.01).
• Richard A. Jackson promoted to COO (eff. 2025-10-01), 8-K filed 2025-10-03 (Items 5.02/7.01).
• OxyChem sale CLOSED (2026-01-02, $9.7B), 8-K filed 2026-01-02 (Items 2.01/7.01).
• FY2025 earnings release, 8-K filed 2026-02-18.
• Debt tender offers (high-coupon/zero-coupon notes), 8-Ks filed 2026-02-19 and 2026-03-09.
• Vicki Hollub to retire / CEO transition to Jackson (eff. 2026-06-01), 8-K filed 2026-05-04 (Items 5.02/5.07/7.01). SEC exhibit: https://www.sec.gov/Archives/edgar/data/0000797468/000095015726000569/ex99-1.htm
• Q1 2026 earnings release, 8-K filed 2026-05-05.
• CrownRock announced (2023-12-12) and CrownRock CLOSED (8-K 2024-08-01, Items 1.01/2.01/3.02).
• Warrant agreement amendment ($22 public warrant strike temporarily cut to $21.30), 8-K filed 2025-03-03.
• Full 36-month 8-K corpus (≈50 filings) available via SEC EDGAR.

Insider transactions (Form 4) — Berkshire & officers/directors

• Warren E. Buffett / Berkshire Hathaway (National Indemnity Co.), >10% owner of OXY (reporting CIK 0001067983; subject CIK 797468). Open-market common purchases (code P) mid-2023 → 2025-02-07; last purchase 2025-02-07 (763,017 sh @ ~$46.82), accession 000095017025018266, filed 2025-02-11; no Form 4 purchases since. Earlier accessions: 000095017023030512, …023055334, …023070147, …023072358, …024011524, …024071037, …024072629, …024074512, …024138710.
• William R. Klesse (director) — discretionary open-market BUY, P 5,000 sh @ $38.98 on 2025-12-16; SEC accession 000162828025057697.
• Officer Form 4s (Hollub, Kerrigan, Jackson, Poladian, et al.) — routine comp mechanics (codes A/F/G/X); available via EDGAR.

Berkshire Hathaway filings (counterparty)

• Berkshire Hathaway Q1 2026 Form 10-Q (brka-20260331), CIK 0001067983 — Berkshire’s OXY holding ~264.94M common shares = ~26.64% of outstanding at 2026-03-31; plus $8.5B 8% Series A preferred and 83.9M warrants @ $59.59. https://www.sec.gov/Archives/edgar/data/0001067983/000119312526202243/brka-20260331.htm
• Berkshire news release, 2026-01-02 — completion of the $9.7B OxyChem acquisition; OXY subsidiary retains OxyChem legacy tort/environmental liabilities. https://www.berkshirehathaway.com/news/jan0226.pdf

PRIMARY — Company Press Releases & Investor Materials (oxy.com)

• “Occidental Announces CEO Succession,” oxy.com, dated 2026-05-01 — Hollub retires eff. 2026-06-01; Richard Jackson named President & CEO; Jackson joins Board. https://www.oxy.com/news/news-releases/occidental-announces-ceo-succession/
• “Occidental Completes Sale of OxyChem,” oxy.com / GlobeNewswire, 2026-01-02 — $9.7B all-cash close. https://www.globenewswire.com/news-release/2026/01/02/3212158/0/en/occidental-completes-sale-of-oxychem.html
• OXY Q4/FY2025 results — oxy.com news release, Feb 2026 (management breakeven/FCF commentary; ~$51/bbl FCF breakeven figure is an IR/transcript figure, NOT in the 10-K — treat as hypothesis).

PRIMARY — Regulator / Government Energy Data

• U.S. EIA, Short-Term Energy Outlook (Global Oil Markets), report dated 2026-05-12 — Strait of Hormuz effectively closed since ~2026-02-28; shut-in ~10.5 Mb/d (Apr), peak ~10.8 Mb/d (May); flows resuming late-May/early-June 2026; Brent avg ~$117 (Apr 2026), forecast ~$95 (FY2026) → ~$79 (FY2027). https://www.eia.gov/outlooks/steo/report/global_oil.php
• U.S. EIA, Spot Prices for Crude Oil and Petroleum Products. https://www.eia.gov/dnav/pet/pet_pri_spt_s1_d.htm
• IEA, Oil Market Report (May 2026) — global demand ~104 Mb/d; largest supply disruption in oil-market history framing. https://www.iea.org/reports/oil-market-report-may-2026
• 26 U.S.C. §45Q (carbon-capture tax credit) and OBBBA (signed 2025-07-04) — DAC credit held at $180/t, EOR/storage parity. (Statute + Global CCS Institute / Payne Institute analyses.)
• U.S. DOI / BOEM — 11th National OCS Leasing Program (Gulf of America lease sales). DOI press materials; Harvard EELP regulatory tracker.

SECONDARY — Market Data & Spot Prices

• Fortune, “Current price of oil as of June 2, 2026” — Brent ~$96.65 (2026-06-02). https://fortune.com/article/price-of-oil-06-02-2026/
• OilPriceAPI, “Oil Prices Today” — Brent ~$97.02 / WTI ~$95.25 (early June 2026). https://www.oilpriceapi.com/oil-prices-today
• Trading Economics — Brent & WTI historical/spot. https://tradingeconomics.com/commodity/brent-crude-oil · https://tradingeconomics.com/commodity/crude-oil
• SEC EDGAR XBRL and public market-data aggregators — quantitative cross-checks (price, market cap, EV, multiples); reconciled to filings.

SECONDARY — News & Trade Press

Hormuz crisis / oil regime

• World Bank Blogs, “Strait of Hormuz disruption sends oil prices surging” (2026). https://blogs.worldbank.org/en/opendata/strait-of-hormuz-disruption-sends-oil-prices-surging
• CNBC, “Brent oil spot price above $120 … Strait of Hormuz” (2026-04-08). https://www.cnbc.com/2026/04/08/dated-brent-oil-price-iran-war-ceasefire-strait-hormuz.html
• ING THINK, “Oil forecasts raised as prolonged Strait of Hormuz disruption continues” (2026-04). https://think.ing.com/articles/oil-forecasts-revised-higher-as-strait-of-hormuz-disruption-drags-on280426/
• Al Jazeera, “Oil prices soar on fears of long supply disruption…” (2026-04-30). https://www.aljazeera.com/news/2026/4/30/oil-prices-soar-on-fears-of-long-supply-disruption-us-siege-of-iran-ports
• Wikipedia, “2026 Strait of Hormuz crisis” / “2026 Iran war fuel crisis” (timeline cross-reference only).

CEO succession

• MarketBeat, “Occidental AGM: CEO Vicki Hollub to Retire June 1, COO Richard Jackson to Take Over” (2026-05-03). https://www.marketbeat.com/instant-alerts/occidental-petroleum-agm-ceo-vicki-hollub-to-retire-june-1-coo-richard-jackson-to-take-over-2026-05-03/
• StockTitan, OXY 8-K filing summary — Jackson named CEO. https://www.stocktitan.net/sec-filings/OXY/

OxyChem sale / Berkshire

• CNBC, “Berkshire Hathaway to buy Occidental’s OxyChem for $9.7 billion…” (2025-10-02). https://www.cnbc.com/2025/10/02/warren-buffett-berkshire-occidental-oxychem.html
• Hart Energy, “Occidental Completes $9.7B Sale of OxyChem to Berkshire Hathaway” (2026-01-02). https://www.hartenergy.com/energy-market-transactions/he-occidental-closes-oxychem-sale-berkshire-hathaway/
• TipRanks, “Buffett’s Berkshire Ups Occidental Stake to 28.3% by Buying More Shares” (Feb 2025) — context for the early-2025 ownership %; note: stake = ~26.6% by Mar 2026 due to share-count dilution, no selling.
• CNBC, “Warren Buffett buys more Occidental after 30% sell-off…” (2025-02-12). https://www.cnbc.com/2025/02/12/warren-buffett-buys-more-occidental-after-30percent-sell-off-from-record-high.html

SECONDARY — Industry / Permian / CCUS Research

• FinancialContent, “Cash Over Barrels: Occidental … in a $66 Oil World” (2026-02-20) — highest remaining-inventory breakeven flag; ~$51 FCF breakeven; resource base.
• Hart Energy, “Oxy Ups Permian Stockpile, Cuts Barnett Breakevens to $35/bbl” (2026); “Analysis: EOG’s Best Permian, Eagle Ford Inventory is Dwindling.”
• Seeking Alpha, “Eyeing Diamondback Energy’s Massive Low-Cost Permian Inventory” (2026).
• PetroEyes / Kavout / World Oil ShaleTech (2026) — Permian Tier-1 exhaustion, per-well productivity decline, rig count.
• Argus / LIUM / RBN Energy (2026) — E&P capex discipline, 2026 planning prices.
• Carbon Herald (JPMorgan 50,000 t CDR offtake from STRATOS); CarbonCredits.com (ADNOC ~$500M DAC deal); GreenFuelJournal / DecarbonFuse (DAC cost/tonne 2026); WEF CDR Technologies (2026); Climeworks (pure-play DAC pricing).